Search results

Hypertension and nephrology

APRIL 24, 2020

[Cardiovascular risk assessment in chronic kidney disease, significance of left ventricular myocardial mass index]

SÁGI Balázs, KÉSŐI István, VAS Tibor, CSIKY Botond, NAGY Judit, KOVÁCS Tibor

[Introduction: Earlier studies have shown that cardiovascular (CV) mortality and morbidity in chronic kidney disease (CKD) often exceed their average population, and left ventricular hypertrophy (LVH) is an independent risk factor for CV disease. However, in CKD, the relationship between LVH, arterial stiffness (AS) and renal function has not yet been fully elucidated. Little data is available on their prognostic role. Aims of our study a) cross-sectional examination of the relationship between left ventricular mass index (LVMI), arterial vascular stiffness, and renal function, b) in our follow-up study, clarification of the LVMI, the prognostic role of AS in patients with CKD, IgA nephropathy (IgAN). Methods: In our cross-sectional study, 79 IgAN patients were examined in our clinic. The myocardial mass index (LVMI) was determined using an estimation formula after echocardiographic measurements. Arterial stiffness was measured using a photoplethizmography technique (PulseTrace) and characterized by the stiffness index (SI). The MDRD formula was used to estimate renal function (GFR) (eGFR, ml/min/1.73 m2). In the prognostic study the primary combined endpoint was total mortality, the most important CV events (stroke, myocardial infarction or cardiovascular interventions such as revascularization) and end stage renal disease. Secondary endpoints were CV and renal endpoints separately. Results: Of the 79 patients included in our cross-sectional study, 50 were men, with an average age of 46 ± 11 years. The mean value of LVMI was 106.66 ± 22.98 g/m2. Patients were divided into groups of 115 g/m2 for males considered to be abnormal and 95 g/m2 for women. LVMI is closely correlated with SI and inversely with eGFR (corr. coeff: 0.358; p <0.05 or -0.526; p <0.001). In case of LVH, SI was significantly higher in both sexes (p = 0.005 in males, p = 0.04 in females). In case of higher LVMI, renal function was significantly lower (p = 0.002 in males, p = 0.01 in females). Metabolic syndrome occurred in several cases in both sexes with LVH, but the difference was only significant in male patients (males 6 vs. 10, p = 0.008; females 2 vs. 4, p = 0.29). In our follow-up study, the presence of LVH in men significantly reduced survival in both primary and secondary endpoints, whereas in women there was no significant difference. Conclusion: In IgAN decreasing of renal function is closely related to left ventricular hypertrophy and vascular stiffness, as well as a close relationship was found between LVMI and AS. Reduced renal function is associated with an increase in LVMI and an increase in AS, which may result in a worse prognosis for both CV and renal outcomes. The underlying role of all these can be assumed to be a common vascular and myocardial pathological remodeling.]

Clinical Neuroscience

NOVEMBER 30, 2018

[Effects of neural therapy on quality of live in patients with inoperable lower extremity artery disease ]

MOLNÁR István, DEÁK Botond Zsolt, HEGYI Gabriella, KOVÁCS Zoltán, KAPÓCS Gábor, SZŐKE Henrik

[Objectives - Our aim was to evaluate the effects of percutaneous neurolysis of lumbal sympathetic ganglions on pain and the resulting changes in quality of life with validated objective and subjective methods. To follow the adverse effects and complications of the procedure. Materials and methods - A prospective, non-randomized, interventional, clinical cohort study under real life conditons was conducted. The time of the observation was 6 months. Palliative neural therapy was performed to reduce the ischemic pain of the affected leg of the patients involved in the study. Prior to treatment and after 35 days, Visual Analogue Scale (VAS) was used to measure the intensity of lower limb pain. The related changes in the quality of life were followed by a general 36-Item Short-Form Health Survey (SF-36) questionnaire. We measured the changes of the patients’ skin temperature and ankle/arm index. The post-treatment results were compared to the pre-treatment results. We compared the results of objective and subjective measures. We followed the side effects and complications of the pain therapy. Each of the examined subjects had obliterative (Fontaine II/b stage) arterial disease of the lower limbs, in which no revascularization intervention was feasible and their ischemic pain was of VAS≥7. Results - Data of 124 patients (69 male, 55 female) could be evaluated. The decrease in intensity of limb pain in the post-treatment period was significant (p=0.001). Quality of life also indicated a significant improvement (p=0.004). Changes in skin temperature and ankle/arm index demonstrated significant improvement (p≤0.005): skin temperature increased from 27.6°C to 31.2°C, the ankle/arm index inceased from 0.67 to 0.83 on average. Changes in objective and subjective measures correlated with each other. No worthening of symptoms, serious adverse events or complications were observed. Conclusion - The chemical denervation of the lumbar sympathetic ganglions with percutaneous application is a minimally invasive intervention, useful in outpatient care, which can be well tolerated by the patient without any significant side effect or complication. Its hyperaemic effect and the pain reduction of the leg can improve the quality of life of the patients.]

Lege Artis Medicinae

OCTOBER 20, 2001



[Transmyocardial laser revascularization (TMLR) is a relatively new technique for the treatment of patients with angina refractory to other medical interventions, such as CABG or PTCA. The laser drills channels through the myocardial wall into the cavity of the ventricle. While the mechanism of action is still debated, clinical data show incentive results suggesting favorable outcome for patients. In the article, the published clinical and experimental data relevant to theoretical mechanisms and clinical results are reviewed.]

Lege Artis Medicinae

JULY 14, 2007



[Acute heart failure may develop in previously healthy hearts. Nevertheless, structural abnormalities can facilitate its development and also, chronic heart failure can progress into acute stage. Considering the total cost of care in the patient's life, this is the most expensive heart disease. The clinical signs and physical abnormalities are usually of diagnostic power, however, instrumental investigations are necessary to recognize complications and to guide therapy. Patients should be monitored in well equipped coronary care units. Therapy consists of medications, coronary revascularization and use of mechanical assist devices.]

Hypertension and nephrology

SEPTEMBER 09, 2010

[Update on diagnostics and therapy of the renal artery stenosis in 2010]


[Results of epidemiological studies indicate the atherosclerotic renal artery stenosis is a common condition, thus development of its diagnostics and therapy has significant importance. Renal artery narrowing can cause hypertension, renal function decline, cardiac failure and the increased cardiovascular risk seriously affects survival perspective of the patients. The evolution of MR technology has a prominent role in renovascular diagnostics. Beyond the detection of arterial stenosis this technique is capable of the functional characterization of the stenosis and the detailed description of the regional kidney tissue damage. Based on the results of clinical studies the relevance of revascularization of the renal artery stenosis remains uncertain. The trials focusing on this issue show methodological imperfections. It remains to be elucidated whether these methodological problems will be tackled in the future based on the present information. This review focuses on the actual findings corresponding to these problems.]

Lege Artis Medicinae

MAY 21, 2006


PAPP Előd, TÓTH Kálmán

[Angiotensin converting enzyme inhibitors have long been basic drugs in the treatment of heart failure. In the preventive treatment of ischaemic heart disease, however, their mortality-reducing effect has only been proved recently. The HOPE was the first trial that showed a beneficial effect of the angiotensin converting enzyme inhibitor ramipril in patients at high risk for cardiovascular diseases. The EUROPA trial showed a positive role of perindopril in the reduction of hard clinical endpoints in relatively low risk patients with known coronary artery disease. The PEACE trial was designed to show a possible group effect of angiotensin converting enzyme inhibitors, but it failed to demonstrate a beneficial effect of trandolapril in patients with coronary artery disease. The latest data from the EUROPA trial and results from three new prevention trials with perindopril or amlodipine plus perindopril combination and with quinapril have been presented recently. Perindopril was administered in patients over 65 years with previous myocardial infarction and with good left ventricle function in the PREAMI study. By the end of the study period, the combined end point and remodelling had decreased significantly. The ASCOT-BPLA trial (amlodipine plus perindopril versus beta-blocker plus diuretic) showed a reduction in all coronary events, in the risk of stroke and in the prevalence of new-onset diabetes mellitus. Quinapril was used in the IMAGINE trial in patients after coronary bypass surgery; the results did not support the hypothesis that early treatment with angiotensin converting enzyme inhibitors improves clinical outcome. Based on these new results, the indication of perindopril has been extended to the reduction of cardiovascular risk in patients with stable coronary artery disease after myocardial infarction or revascularization.]

Hungarian Radiology

JUNE 20, 2007

[Correlation of clinical parameters with myocardial perfusion grades in acute myocardial infarct patients]

UNGI Tamás, JÓNÁS Zsuzsanna, UNGI Imre, SASI Viktor, ZIMMERMAN Zsolt, PALKÓ András

[INTRODUCTION - The prognosis after opening the obstructed infarct-related coronary artery is influenced by several factors. In routine clinical practice revascularization is considered to be successful when the restoration of epicardial blood flow is complete. However, functional impairment in the myocardium can occur even with open epicardial arteries. There are two angiographic parameters closely related to myocardial viability: myocardial blush grade (MBG) that describes the quantity of contrast material in the myocardium, and TIMI myocardial perfusion grade (TMP) that describes its outflow dynamics. Our goal was to assess the prognostic value of these two parameters in the framework of a prospective clinical study. PATIENTS AND METHODS - We compared the two parameters based on visual estimation (MBG and TMP) with those characterizing myocardial impairment, such as ejection fraction (EF), wall motion score index (WMSI), creatine-kinase release and chest pain score in 22 patients with acute myocardial infarction and successful revascularization. Our results were obtained by Spearman's rank correlation and χ2-tests at a confidence interval of 95%. RESULTS - Close correlation with TMP was found in case of both parameters measured by echocardiography (EF: r=0.59, p=0.02; WMSI: r=-0.51, p=0.046). These results were supported by the correlation with creatinekinase release (r=-0.54, P=0.01). By the present number of patients, MBG does not show significant correlation with the measured clinical parameters. Presence of chest pain is associated neither with TMP nor with MBG. CONCLUSIONS - Assessing myocardial perfusion by visual evaluation provides useful prognostic information. The extent of chest pain does not indicate myocardial dysfunction. The clearence of the dye (used in TMP definition) is more characteristic to myocardial viability than maximal contrast density (used in MBG definition).]

Lege Artis Medicinae

NOVEMBER 30, 2006


TÓTH Csaba

[Current guidelines recommend drug treatment as firstline therapy for stable angina. If adequate symptom relief cannot be achieved with pharmacological management, or if myocardial ischaemia progresses, interventional revascularization procedures should be considered. Based on current guidelines, this should be either coronary artery bypass grafting or percutaneous coronary intervention. Recurrent angina refers to the persistence or reemergence of angina symptoms after a coronary revascularization procedure. This clinical situation indicates the repeat of coronarography as soon as possible. The repeated coronarography, however, often will not confirm progression or restenosis. The pathology of this clinical form of recurrent angina is not exactly known. As symptoms are frequently seen in the absence of abnormal coronary blood flow, vasodilator drugs are of limited effectiveness in recurrent angina. For this reason new, non-haemodynamic treatment approaches have been suggested. Among these, agents that help optimise cardiac metabolism are of particular interest. Trimetazidine acts on the energy metabolism of myocardial cells by reducing the reliance of myocardial metabolism on fatty acid oxidation and lifting the feedback inhibition of the glucose oxidation pathway. Moreover, trimetazidine reduces intracellular acidosis. These beneficial effects on cellular processes make trimetazidine the first representative of cardioprotective drugs. In randomized, placebo-controlled clinical trials on patients after revascularization, trimetazidine significantly reduced the number of angina episodes, decreased the ECG signs and the levels of biochemical markers of myocardial ischaemia, and improved exercise test parameters compared to placebo. The spectrum of benefits of this drug in stable angina ranges from decreasing the need for surgical intervention to improving the outcome and diminishing the symptoms of angina pectoris following revascularization.]

Lege Artis Medicinae

AUGUST 20, 2002

[Quality assessment in the management of acute coronary syndromes]


[INTRODUCTION AND METHODS - Quality monitoring activities are essential for improving the care of acute coronary patients. The aim of our study was to establish a registry and assess the adherence to widely used quality indicators. We investigated two groups of patients, those admitted to our Intensive Care Unit with the diagnosis of acute myocardial infarction (Group 1) and unstable angina (Group 2). RESULTS - Group 1. consisted of 173 patients, of whom 60% was eligible for thrombolysis. In 5 cases no acute reperfusion therapy was done. For reperfusion we used systemic thrombolysis in 74% and primary coronary angioplasty in 26%. The prehospital delay was 150 minutes, the ”door-to-needle” time and the ”door-toballoon” time were 30 minutes and 102 minutes, respectively. 95% of the patients received aspirin, 79% beta-blocker, 82% angiotensin converting enzyme inhibitor and 39% cholesterol lowering medications. Group 2. included 84 patients, most of them had high risk features according to the Braunwald classification and the American College of Cardiology, American Heart Association guideline. Coronary angiography was performed in 80 cases. Regarding revascularization, 43 patients underwent coronary bypass surgery, 30 percutan angioplasty with stent implantation in 18. In this group aspirin was given in 82, unfractionated heparin in 9, low molecular weight heparin in 49, glycoprotein IIb/IIIa inhibitor in 15 cases. 21 patients received intravenous nitroglycerin, 70 patients betablocker and 57 patients cholesterol lowering drugs. DISCUSSION - Quality management is extremely useful in assessing our practice, our shortcomings and developments.]